"Scientist's Custom Gene-Editing Tools Set to Generate Billions"

Benjamin Oakes, co-founder of Scribe Therapeutics, is developing customized gene-editing tools using specialized Crispr proteins to target a range of diseases. The company has secured over $120 million in venture investments and has partnerships with major pharmaceutical companies potentially worth over $4 billion. Scribe Therapeutics is using a different set of proteins called "CasX" to improve the precision and controllability of gene editing therapies. The company's primary focus is on delivering gene editing treatments directly to patients, rather than removing and editing cells outside the body. Scribe's innovative approach has attracted investors and partnerships, positioning it as a promising player in the Crispr startup market.